Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)
China
· Delayed Price · Currency is CNY 5.47
-0.04 (-0.73%)
Feb 21, 2025, 3:04 PM CST
SHE:002550 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 293.59 | 181.86 | 323.41 | 181.08 | -132.02 | 262.56 | Upgrade
|
| Depreciation & Amortization | 67.19 | 67.19 | 64.76 | 69.43 | 70.25 | 65.47 | Upgrade
|
| Other Amortization | 5.78 | 5.78 | 3.55 | 5.67 | 3.39 | 2.36 | Upgrade
|
| Loss (Gain) From Sale of Assets | -25.35 | -25.35 | -57.59 | - | - | 0.03 | Upgrade
|
| Asset Writedown & Restructuring Costs | 7.77 | 7.77 | 0.24 | 0.46 | 1.6 | 0.42 | Upgrade
|
| Loss (Gain) From Sale of Investments | -8.83 | -8.83 | 3.82 | -0.64 | -16.03 | -104.92 | Upgrade
|
| Provision & Write-off of Bad Debts | -19.02 | -19.02 | 15.3 | -52.68 | 5.04 | -1.52 | Upgrade
|
| Other Operating Activities | -32.87 | 19.11 | -46.62 | 6.11 | 390.89 | 46.27 | Upgrade
|
| Change in Accounts Receivable | 420.4 | 420.4 | -165.9 | 55.37 | 49.78 | -120.75 | Upgrade
|
| Change in Inventory | -77.46 | -77.46 | -136.12 | -84.79 | -73.03 | -0.04 | Upgrade
|
| Change in Accounts Payable | -50.63 | -50.63 | -83.14 | -86.65 | 82.57 | 28.81 | Upgrade
|
| Change in Other Net Operating Assets | 1.98 | 1.98 | 4.37 | 4.12 | 4.07 | - | Upgrade
|
| Operating Cash Flow | 593.08 | 533.33 | -71.47 | 103.56 | 317.28 | 161.55 | Upgrade
|
| Operating Cash Flow Growth | 58.45% | - | - | -67.36% | 96.40% | 534.87% | Upgrade
|
| Capital Expenditures | -87.66 | -100.33 | -70.99 | -90.37 | -62.53 | -100.68 | Upgrade
|
| Sale of Property, Plant & Equipment | 13.5 | 32.3 | 0.11 | 0 | 0.02 | 1.7 | Upgrade
|
| Cash Acquisitions | - | - | -1.67 | - | - | -0.04 | Upgrade
|
| Investment in Securities | -108.5 | -108.5 | -121.08 | 177.22 | 489.88 | 190.26 | Upgrade
|
| Other Investing Activities | 56.82 | 1.43 | 3.65 | 8.43 | 32.17 | 93.78 | Upgrade
|
| Investing Cash Flow | -125.83 | -175.1 | -189.98 | 95.28 | 459.53 | 185.03 | Upgrade
|
| Short-Term Debt Issued | - | 435.51 | 461.27 | 124.95 | 326.15 | 652.37 | Upgrade
|
| Total Debt Issued | 35.51 | 435.51 | 461.27 | 124.95 | 326.15 | 652.37 | Upgrade
|
| Short-Term Debt Repaid | - | -480 | -440 | -77.43 | -628.54 | -740.49 | Upgrade
|
| Total Debt Repaid | -35.48 | -480 | -440 | -77.43 | -628.54 | -740.49 | Upgrade
|
| Net Debt Issued (Repaid) | 0.03 | -44.49 | 21.27 | 47.52 | -302.39 | -88.12 | Upgrade
|
| Issuance of Common Stock | - | - | 144.9 | - | 171.84 | - | Upgrade
|
| Repurchase of Common Stock | -69.59 | -30.09 | - | -0.19 | -0.3 | - | Upgrade
|
| Common Dividends Paid | -151.92 | -158.79 | -155.16 | -151.51 | -313.62 | -170.14 | Upgrade
|
| Other Financing Activities | -68.18 | 42.5 | - | - | - | -309.52 | Upgrade
|
| Financing Cash Flow | -289.66 | -190.87 | 11.02 | -104.17 | -444.47 | -567.77 | Upgrade
|
| Foreign Exchange Rate Adjustments | -4.81 | -1.6 | 41.89 | 7.39 | -18.6 | 4.37 | Upgrade
|
| Net Cash Flow | 172.77 | 165.76 | -208.55 | 102.06 | 313.74 | -216.83 | Upgrade
|
| Free Cash Flow | 505.42 | 433 | -142.46 | 13.19 | 254.74 | 60.87 | Upgrade
|
| Free Cash Flow Growth | 71.67% | - | - | -94.82% | 318.51% | - | Upgrade
|
| Free Cash Flow Margin | 32.48% | 23.87% | -6.18% | 0.70% | 15.28% | 3.63% | Upgrade
|
| Free Cash Flow Per Share | 0.39 | 0.33 | -0.11 | 0.01 | 0.21 | 0.05 | Upgrade
|
| Cash Income Tax Paid | 140.32 | 45.16 | 26.55 | 81.87 | 79.15 | 84.59 | Upgrade
|
| Levered Free Cash Flow | 385.71 | 339.38 | -216.74 | -40.56 | 609.25 | -454.78 | Upgrade
|
| Unlevered Free Cash Flow | 389.42 | 343.09 | -213.46 | -39.53 | 614.53 | -443.08 | Upgrade
|
| Change in Net Working Capital | -208.4 | -272.06 | 354.27 | 123.62 | -468.1 | 561.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.